Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 08/23/2017 (Stipulation and order of dismissal (voluntary dismissal))

Filing Date: June 20, 2017

Threshold Pharmaceuticals, Inc. is a biotechnology company developing targeted cancer therapeutics based on the hypoxic conditions commonly found in the tumor microenvironment.

According to the Complaint, on March 17, 2017, Molecular Templates, Inc., (“Molecular”) and the Company announced that they had entered into an Agreement and Plan of Merger pursuant to which Trojan Merger Sub, Inc, a wholly owned subsidiary of Threshold, will merge with and into Molecular, with Molecular surviving as a wholly owned subsidiary of Threshold in an all-stock transaction (the “Proposed Transaction”).

The Complaint alleges on May 15, 2017, Defendants issued materially incomplete and misleading disclosures in the Form S-4 Registration Statement filed with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Registration Statement is deficient and misleading in that it fails to provide adequate disclosures of all material information related to the Proposed Transaction.

This case was voluntarily dismissed on August 23, 2017.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.